Revenue fell 10.27% and net profit dropped 94% year-over-year, mainly due to pricing adjustments and increased R&D investment. The company advanced 38 products into clinical stages, secured a major international licensing deal, and maintained high R&D intensity despite cash flow pressure.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.